CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 29, 2025– Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 29, 2025– Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious…
No Comments
Leave a comment Cancel